An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
← catalyst calendarNCT05649748 · readout in 133 d
Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
91actual
Sites
45
Countries
Argentina, Austria, Belgium +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Arterial Hypertension
Interventions
- Drug: Treprostinil Palmitil — also filed as INS1009
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity
measured From screening up to last follow up visit (Up to approximately 26 months)
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed